Keywords: DOAC; intracerebral hemorrhage; warfarin; stroke;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: DOAC; Antiplatelets; Coronary stent; Atrial fibrillation; Intracranial hemorrhage; Major hemorrhage; Medicare;
Keywords: direct oral anticoagulants; DOAC; novel oral anticoagulants; NOAC; dentoalveolar surgery;
Keywords: cerebrovascular accident; myocardial infarction; new onset; warfarin; AF; atrial fibrillation; ACS; acute coronary syndrome; COPD; chronic obstructive pulmonary disease; CHADS2; congestive heart failure, hypertension, age >75, diabetes mellitus, stroke or
Keywords: Atrial fibrillation; Stroke; Catheter ablation; Oral anticoagulant; VKA; DOAC; Thromboembolic events; Systematic review; Meta-analysis;
Keywords: CDT; Catheter Directed Thrombolysis; CT; Computed tomography; CTA; CT angiography; DOAC; direct oral anticoagulant; DUS; Doppler ultrasound; DVT; deep vein thrombosis; ECMO; Extra Corporeal Membrane Oxygenation; ICH; intracranial hemorrhage; ICU; intensiv
Keywords: OAC; Oral anticoagulant; VKA; Vitamin K antagonist; DOAC; Direct oral anticoagulant; PCC; Prothrombin complex concentrate; 4F-PCC; Four factor PCC; 3F-PCC; Three factor PCC; aPCC; Activated PCC; FFP; Fresh frozen plasma; AF; Atrial fibrillation; TE; Throm
Keywords: Idarucizumab; aripazine; andexanet alfa; thromboprophylaxis; direct oral anticoagulants; DOAC; reversal agents; pharmacology of DOACs;
Keywords: Antiphospholipid syndrome; Direct oral anticoagulants; Antiphospholipid antibodies; Recurrent thrombosis; Triple positivity; Arterial thrombosis; APS; antiphospholipid syndrome; aPL; antiphospholipid antibodies; VKA; vitamin K antagonist; DOAC; direct ora
Keywords: cardiovascular disease; essential medicines; NCDs; WHO Essential Medicines List; ACE; angiotensin-converting enzyme; ARB; angiotensin receptor blockers; ARV; antiretroviral drug; DOAC; direct oral anticoagulant; EML; List of Essential Medicines; FDC; fixe
Keywords: critically ill; heparin; heparin-induced thrombocytopenia; thrombocytopenia; thrombosis; APTT; activated partial thromboplastin time; DIC; disseminated intravascular coagulation; DOAC; direct oral anticoagulant; ECMO; extracorporeal membrane oxygenation;
Keywords: Minor cutaneous surgery; Haemorrhage; Aspirin; Warfarin; Clopidogrel; DOAC;
Keywords: PT; prothrombin time; PT-INR; prothrombin time-international normalized ratio; APTT; activated partial thromboplastin time; CT; computed tomography; IVR; interventional radiography; LCA; left colic artery; SRA; superior rectal artery; DOAC; direct oral an
Keywords: DOAC; direct oral anticoagulant; EMA; European Medicines Agency; FDA; Food and Drug Administration; IS; internal standard; SPE; solid phase extraction; (UP)LC/MS/MS; (ultra-performance) liquid chromatography coupled to tandem mass spectrometry; QC; qualit
Keywords: anticoagulation; DOAC; nephrotic; thrombosis;
Keywords: AF; atrial fibrillation; ARISTOTLE(âJ); Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (âJapanese patients); AVERROES; Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who
Keywords: AHA; American Heart Association; CDT; catheter directed thrombolysis; CVI; chronic venous insufficiency; DOAC; direct oral anticoagulant; DVT; deep-vein thrombosis; FU; follow-up; ISTH; International Society on Thrombosis and Haemostasis; LMWH; low molecu
Keywords: ADP; adenosine diphosphate; AF; atrial fibrillation; DOAC; direct oral anti-coagulant; MPs; microparticles; NSAIDs; nonsteroidal anti-inflammatory drugs; TF; tissue factor; TRAP; thrombin receptor activating peptide; VKA; vitamin-K antagonist; VWF; von Wi
Keywords: APT; antiplatelet therapy; CT; computed tomography; CTA; computed tomography angiography; DOAC; direct oral anticoagulant; DDAVP; desmopressin; FFP; fresh frozen plasma; ICH; intracerebral hemorrhage; INR; international normalized ratio; mRS; modified Ran
Keywords: Prothrombin time-international normalized ratio; oral anticoagulant; atrial fibrillation; warfarin; time in therapeutic range; DOAC;
Keywords: Cerebrovascular complication; DOAC; direct thrombin inhibitor; factor Xa inhibitor; efficacy and safety; PMDA;
Keywords: antithrombotic therapy; deep venous thrombosis; direct oral anticoagulants; laboratory; pulmonary embolism; AF; atrial fibrillation; APTT; activated partial thromboplastin time; CHEST; American College of Chest Physicians; DOAC; direct oral anticoagulant;
Keywords: ACT; activated clotting time; AF; atrial fibrillation; ASAP; Aspirin Plavix Feasibility Study; CAP; Continued Access Protocol; CT; computed tomographic; CV; Cardiovascular; CVD; Cardiovascular disease; DAPT; dual anti-platelet therapy; DAT; device associa
Keywords: atrial fibrillation; major bleeding; oral anticoagulants; postmarketing drug safety; aRR; adjusted relative risk; DOAC; direct oral anticoagulant;
Keywords: DOAC; Inter-individual variability; Intra-individual variability; Dilute thrombin time; Anti-FXa; Creatinine clearance;
Keywords: Idarucizumab; Andexanet alfa; DOAC; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Antidote; Praxbind; ANNEXA-A; ANNEXA-R;
Keywords: DOAC; Anticoagulation; Venous thromboembolism; Atrial fibrillation;
Keywords: anticoagulation; atrial fibrillation; stroke; ACS; acute coronary syndrome(s); AF; atrial fibrillation; DOAC; direct-acting oral anticoagulant; DAPT; dual antiplatelet therapy; FFP; fresh frozen plasma; ICH; intracranial hemorrhage; INR; international n
Keywords: AF; atrial fibrillation; cW; continuous warfarin; dOAC; discontinued warfarin; LA; left atrium; NOAC; new oral anticoagulants; OAC; oral anticoagulation; RF; radiofrequency; VKA; vitamin K antagonists; Atrial fibrillation; Catheter ablation; Heparin; Oral
Keywords: Oral anticoagulation; ischemic stroke; secondary prevention; hemorrhagic transformation; DOAC; atrial fibrillation
Keywords: outpatient PE; pulmonary embolism; CTPA; CT pulmonary arteriography; CUS; compression ultrasound; DOAC; direct oral anticoagulant; PE; pulmonary embolism; PESI; Pulmonary Embolism Severity Index;
Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants
Keywords: DOAC; Antiphospholipid syndrome; Laboratory measurement; DRVVT assay; Interference; Laboratory diagnosis; Clinical trials and methods; Autoantigens and autoantibodies;
Simple method for removing DOACs from plasma samples
Keywords: DOAC; Dabigatran; Apixaban; Rivaroxaban; Edoxaban; APTT; dRVVT; Lupus anticoagulant; Clotting tests; DOAC adsorbent;
Transition of care for patients with venous thromboembolism: Rationale, design and implementation of a quality intervention project conducted at American Thrombosis and Hemostasis Network (ATHN) affiliated sites
Keywords: ATHN; American Thrombosis and Hemostasis Network; CDIM; comprehensive discharge instruction modules; DOAC; direct oral anticoagulant; DVT; deep vein thrombosis; EMR; electronic medical record; HTC; hemophilia treatment center; QI; quality intervention; TO
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
Keywords: DOAC; direct oral anticoagulant; NVAF; non-valvular atrial fibrillation; ATC; Anatomic Therapeutic Classification system; ICD-10; International Classification of Diseases version 10; HR; hazard ratio; CI; confidence interval; TIA; transient ischemic attac
Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study
Keywords: Warfarin; Vitamin- K antagonists; Direct oral anticoagulant; DOAC; Adherence; Patient care; Atrial fibrillation; Venous thromboembolism; Quality of life;
Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
Keywords: DOAC; direct oral anticoagulant; DVT; deep vein thrombosis; LMWH; low-molecular-weight heparin; PE; pulmonary embolism; VKA; vitamin K antagonist; VTE; venous thromboembolism; VTE-AL; venous thromboembolism of atypical location; VTE-TL; venous thromboembo
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke
Keywords: Stroke volume; recurrent; NOAC; DOAC; direct thrombin inhibitor; dabigatran; factor Xa inhibitor; rivaroxaban; apixaban; edoxaban; warfarin;
Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU
Keywords: Antithrombotic; Anticoagulation; Antiplatelet; Surgery; Antitrombótico; Anticoagulación; Antiagregación; CirugÃa; AF; atrial fibrillation; DAPT; dual antiplatelet therapy; DES; drug-eluting stent; DOAC; direct oral anticoagulant; PCI; percutaneous cor
Global Prospective Safety Analysis of Rivaroxaban
Keywords: atrial fibrillation; real-world; rivaroxaban; safety; stroke prevention; XANTUS; AE; adverse event; AF; atrial fibrillation; CNS; central nervous system; CrCl; creatinine clearance; DOAC; direct oral anticoagulant; ICH; intracranial hemorrhage; ISTH; Inte
BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications
Keywords: ABC; ATP-binding cassette; AUC; area under the time-concentration curve; BCRP; breast cancer resistance protein; Cmax; maximum concentration; CYP; cytochrome P450; DOAC; direct oral anti-coagulant; GI; gastrointestinal; MRP1; multidrug resistance protei
Arthrocentesis and Joint Injection in Patients Receiving Direct Oral Anticoagulants
Keywords: DOAC; direct oral anticoagulant; FDA; Food and Drug Administration; INR; international normalized ratio; VTE; venous thromboembolism;
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial
Keywords: Anticoagulation; Atrial fibrillation; Ablation; Edoxaban; DOAC;
Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety of rivarox
Keywords: Anticoagulants; DOAC; Non-valvular atrial fibrillation; Stroke; General practitioner;
Cardiovascular Complications of Cancer Therapy
Keywords: cancer therapy; cardiovascular complication; hypertension; radiation therapy; thromboembolism; AF; atrial fibrillation; CAD; coronary artery disease; CTA; computed tomography angiography; DOAC; direct oral anticoagulant; DVT; deep vein thrombosis; ECG; el
Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis
Keywords: Hemorrhage; Novel Anticoagulant; DOAC; AF; atrial fibrillation; CI; confidence interval; CRNM; clinically relevant nonmajor; OR; odds ratio; GI; gastrointestinal; HR; hazard ratio; NOAC; novel oral anticoagulant; RCT; randomized controlled trial; VTE; ven
CorrespondenceStability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment
Keywords: C; Celsius; DOAC; Direct oral anticoagulant; Anticoagulants; Apixaban; Dabigatran; Drug monitoring; DOAC; Rivaroxaban;
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial
Keywords: anticoagulants; coronary disease; direct-acting oral anticoagulants; fibrillation; percutaneous coronary intervention; AF; atrial fibrillation; DAPT; dual antiplatelet therapy; DOAC; direct-acting oral anticoagulants; MI; myocardial infarction; PCI; percu
An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery
Keywords: direct or novel or target-specific oral anticoagulant; DOAC; NOAC; TSOAC; dabigatran; rivaroxaban; apixaban; edoxaban; betrixaban; oral surgery
Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists
Keywords: AUB; abnormal uterine bleeding; BMI; body mass index; DVT; deep-vein thrombosis; FIGO; International Federation of Gynecology and Obstetrics; IQR; interquartile range; LMWH; low-molecular-weight heparin; DOAC; direct-acting oral anticoagulant; PE; pulmona